CLDN8 and colitis: By inhibiting miR-223, the mirVana® miRNA inhibitor reactivated CLDN8 in colitis tissues (Fig. 6d-f, P <0.01), in parallel with the recovery in loss of body weight, and improvement of histological appearance, histological score and MPO activity, and the preservation of the integrity of the intestinal epithelial barrier.